SUBA-伊曲康唑在血液恶性肿瘤或异基因造血干细胞移植患者中的预防性应用:血清水平、安全性与耐受性
单中心前瞻性队列研究以历史对照组为比较,评估新型SUBA-伊曲康唑对比传统伊曲康唑口服液在异基因HSCT或中高危侵袭性真菌感染血液恶性肿瘤患者中的预防效果。结果显示SUBA组更快达到治疗浓度且个体间变异更小,稳态谷浓度更高,治疗失败率数值上更低但差异无统计学意义。
要点
- SUBA-伊曲康唑达治疗浓度中位时间6天,显著快于口服液的14天(P<0.0001)
- 第10天达治疗浓度比例SUBA组69% vs 口服液组21%(P<0.0001)
- SUBA组稳态谷浓度更高且个体间变异更小(1577 ng/mL,CV 35% vs 1218 ng/mL,CV 60%,P<0.001)
核心结论
- SUBA-伊曲康唑用于异基因HSCT或中高危IFI血液恶性肿瘤患者预防时,比传统口服液更快达到治疗浓度且个体间变异更小。
研究设计与样本
- 单中心前瞻性队列研究,采用历史对照组作为比较。
- 共评估57例患者:SUBA-伊曲康唑组27例,口服液伊曲康唑组30例。
主要发现
- SUBA组达治疗浓度中位时间6天(95%CI 5-11),口服液组14天(95%CI 12-21),P<0.0001。
- 第10天达治疗浓度比例SUBA组69%(95%CI 44%-81%),口服液组21%(95%CI 7%-33%),P<0.0001。
- 稳态平均谷浓度SUBA组1577 ng/mL(CV 35%),口服液组1218 ng/mL(CV 60%),P<0.001。
- 治疗失败SUBA组2例(7.4%)均因黏膜炎停药,口服液组7例(23.3%)因亚治疗浓度5例、黏膜炎1例、胃肠道不耐受1例,P=0.096。
临床怎么用
- 对于需要伊曲康唑预防IFI的异基因HSCT或中高危血液恶性肿瘤患者,SUBA-伊曲康唑可更快达到治疗浓度且个体间变异更小。
局限性
- 单中心研究,样本量较小(共57例),采用历史对照而非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess therapeutic levels, safety and tolerability of a novel formulation SUBA-itraconazole (where SUBA stands for SUper BioAvailability) when compared with conventional itraconazole liquid when used as antifungal prophylaxis in patients undergoing allogeneic HSCT or in haematological malignancy patients with an intermediate/high risk of invasive fungal infection (IFI). METHODS: This was a single-institution, prospective cohort study using a historical control group as the comparator. RESULTS: A total of 57 patients were assessed: 27 in the SUBA-itraconazole cohort and 30 in the liquid itraconazole cohort. Therapeutic concentrations were achieved significantly more quickly in the SUBA-itraconazole group: median of 6 (95% CI 5-11) days versus 14 (95% CI 12-21) days in the liquid itraconazole group (P < 0.0001). At day 10, therapeutic concentrations were achieved in 69% (95% CI 44%-81%) of the SUBA-itraconazole group versus 21% (95% CI 7%-33%) of the liquid itraconazole group (P < 0.0001). The mean trough serum concentrations at steady-state of SUBA-itraconazole were significantly higher, with less interpatient variability [1577 ng/mL, coefficient of variation (CV) 35%] versus liquid itraconazole (1218 ng/mL, CV 60%) (P < 0.001). There were two (7.4%) treatment failures in the SUBA-itraconazole group, both due to cessation of therapy for mucositis, compared with seven (23.3%) treatment failures in the liquid itraconazole group, due to subtherapeutic levels (five), mucositis (one) and gastrointestinal intolerance (one) (P = 0.096). CONCLUSIONS: The use of the SUBA-itraconazole formulation was associated with more rapid attainment of therapeutic levels with less interpatient variability compared with conventional liquid itraconazole when used as IFI prophylaxis in allogeneic HSCT or intermediate-/high-IFI risk haematological malignancy patients.
引用
- Lindsay J, Sandaradura I, Wong K, et al. Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. J Antimicrob Chemother. 2017. PMID: 28961894. doi:10.1093/jac/dkx295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。